| Recruiting | HB-adMSCs for the Treatment of Crohn's Disease Crohn Disease (CD) | Phase 2 | 2026-03-01 |
| Withdrawn | HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis Juvenile Idiopathic Arthritis (JIA) | Phase 2 | 2026-01-01 |
| Active Not Recruiting | "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis" Relapsing Remitting Multiple Sclerosis (RRMS), Multiple Sclerosis | Phase 2 | 2025-05-02 |
| Completed | Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 Syndr Post COVID-19 Syndrome | Phase 2 | 2022-02-02 |
| Completed | Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Multiple Sclerosis | Phase 2 | 2021-11-24 |
| Completed | Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD) Parkinson Disease | Phase 2 | 2021-07-16 |
| Completed | Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate) Parkinson Disease | Phase 2 | 2021-06-28 |
| Terminated | Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19 COVID-19 | Phase 2 | 2020-06-30 |
| Completed | A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19. COVID-19 | Phase 2 | 2020-05-14 |
| Completed | A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19 COVID-19 | Phase 2 | 2020-04-20 |
| No Longer Available | "Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis" Primary Lateral Sclerosis, Adult, 1 | — | — |
| No Longer Available | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells f Cerebral Palsy | — | — |
| Available | "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allog Multiple System Atrophy | — | — |
| No Longer Available | An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Chronic Inflammatory Demyelinating Polyneuropathy | — | — |
| No Longer Available | Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Scleros Amyotrophic Lateral Sclerosis | — | — |
| No Longer Available | Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain. Knee Pain Chronic, Osteo Arthritis Knee | — | — |
| No Longer Available | Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells f Spinal Cord Injuries | — | — |
| No Longer Available | Individual Patient Expanded Access IND to Treat Polyneuropathy Polyneuropathies | — | — |
| No Longer Available | Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematos System; Lupus Erythematosus | — | — |
| No Longer Available | Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Diseas Parkinson Disease | — | — |
| No Longer Available | Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 Syndrome Post COVID-19 Syndrome | — | — |
| No Longer Available | Individual Patient Expanded Access IND for the Treatment of Stroke Stroke, Stroke, Ischemic | — | — |
| No Longer Available | HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy. Congenital Muscular Dystrophy Due to Lamin A/C Mutation | — | — |
| No Longer Available | Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain. Chronic Pain | — | — |
| No Longer Available | Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's Disease Parkinson Disease | — | — |
| Available | Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patie Brain Injury | — | — |